background
nonventil
hospitalacquir
pneumonia
nvhap
seriou
nosocomi
infect
increasingli
attribut
antibioticresist
bacteria
method
retrospect
casecontrol
studi
compar
patient
without
nvhap
januari
decemb
barnesjewish
hospit
urban
academ
medic
center
st
loui
missouri
one
hundr
seventyfour
consecut
patient
nvhap
enrol
random
sampl
control
patient
match
age
sex
race
hospit
admiss
date
select
total
potenti
match
control
subject
nvhap
pathogenneg
case
respiratori
virus
identifi
patient
gramneg
bacteria
seen
patient
gramposit
bacteria
identifi
patient
individu
nvhap
develop
like
die
vs
p
requir
intens
care
vs
p
mechan
ventil
vs
p
longer
hospit
length
stay
day
rang
day
vs
day
rang
day
p
casecontrol
studi
identifi
strong
associ
hospit
mortal
nvhap
patient
acquir
nvhap
time
greater
odd
death
ci
conclus
occurr
nvhap
associ
signific
increas
mortal
use
intens
care
mechan
ventil
hospit
length
stay
also
found
respiratori
virus
import
caus
nvhap
find
suggest
effort
aim
success
prevent
nvhap
could
improv
patient
outcom
reduc
healthcar
cost
chest
key
word
antibiot
resist
outcom
pneumonia
editori
comment
see
page
abbrevi
hap
hospitalacquir
pneumonia
mdr
multidrugresist
nvhap
nonventil
hospitalacquir
pneumonia
vap
ventilatorassoci
pneumonia
affili
hospitalacquir
pneumonia
hap
frequent
sever
infect
hospit
patient
report
focus
hap
acquir
icu
form
ventilatorassoci
pneumonia
vap
increasingli
antibioticresist
pathogen
includ
extendedspectrum
betalactamaseproduc
carbapenemresist
enterobacteriacea
methicillinresist
staphylococcu
aureu
multidrugresist
mdr
nonfer
gramneg
bacilli
pseudomona
aeruginosa
acinetobact
baumannii
stenotrophomona
maltophilia
associ
hap
respiratori
virus
also
recent
identifi
potenti
import
caus
pathogen
hap
antibioticresist
bacteria
well
respiratori
virus
pose
ongo
challeng
hospit
patient
treatment
prevent
transmiss
pathogen
patient
patient
unfortun
clinic
studi
assess
impact
hap
patient
outcom
guidelin
prevent
hap
direct
vap
littl
attent
focus
nonventil
hap
nvhap
like
result
greater
sever
ill
patient
icu
set
well
abil
precis
defin
presenc
true
infect
ventil
patient
pneumonia
use
diagnost
techniqu
bal
quantit
cultur
avail
studi
suggest
nvhap
appear
caus
microorgan
outcom
similar
vap
howev
lack
control
studi
focus
nvhap
quantit
determin
impact
nosocomi
infect
patient
outcom
avail
data
could
influenc
hospit
physician
increas
effort
aim
prevent
nvhap
well
improv
treatment
nosocomi
infect
therefor
perform
casecontrol
studi
describ
caus
pathogen
associ
nvhap
determin
influenc
nvhap
patient
outcom
singlecent
retrospect
casecontrol
studi
patient
nvhap
perform
barnesjewish
hospit
urban
academ
medic
center
st
loui
missouri
januari
decemb
studi
protocol
approv
washington
univers
institut
review
board
irb
inform
consent
waiv
adult
patient
year
age
admit
hospit
h
elig
particip
patient
exclud
transfer
outsid
hospit
defin
nvhap
case
accord
american
thorac
societi
posit
statement
nosocomi
pneumonia
patient
respiratori
cultur
specimen
obtain
studi
period
screen
studi
entri
nvhap
defin
new
progress
radiograph
infiltr
develop
h
hospit
admiss
plu
least
two
follow
clinic
featur
fever
c
leukocytosi
cellsl
leukopenia
cellsl
purul
secret
charlson
comorbid
index
use
summ
score
underli
diseas
state
presenc
new
progress
radiograph
infiltr
base
interpret
chest
radiograph
boardcertifi
radiologist
blind
studi
patient
chart
identifi
new
progress
infiltr
review
one
investig
h
k
confirm
radiograph
find
two
investig
b
c
identifi
patient
meet
case
definit
nvhap
pneumonia
classifi
pathogenneg
respiratori
cultur
result
appli
molecular
techniqu
fail
identifi
pathogen
pathogenposit
pneumonia
defin
growth
pathogen
organ
sputum
tracheal
aspir
bronchoscop
blind
bal
fluid
tracheal
aspir
bronchoscop
blind
bal
fluid
obtain
patient
nvhap
within
h
respiratori
failur
develop
addit
posit
urinari
antigen
test
result
legionella
qualifi
posit
cultur
result
posit
qualit
nucleic
acid
multiplex
test
result
respiratori
virus
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
filmarray
respiratori
panel
biofir
diagnost
select
control
subject
use
risk
set
sampl
scheme
four
control
subject
select
case
match
age
sex
race
hospit
admiss
date
within
month
case
patient
admiss
date
random
sampl
match
control
patient
select
case
nvhap
use
random
number
gener
main
end
point
evalu
hospit
mortal
secondari
measur
includ
icu
admiss
mechan
ventil
length
stay
readmiss
index
hospit
primari
data
analysi
compar
patient
nvhap
without
nvhap
categor
variabl
compar
use
c
fisher
exact
test
appropri
continu
variabl
compar
use
mannwhitney
u
test
data
match
casecontrol
studi
analyz
use
condit
fixedeffect
logist
analysi
model
good
fit
assess
hosmerlemeshow
test
test
twotail
p
valu
consid
signific
statist
analys
perform
use
ibm
spss
statist
version
spss
journalpublicationschestnetorg
total
case
nvhap
identifi
control
subject
select
fig
stenotrophomona
maltophilia
moraxella
catarrhali
citrobact
koseri
achromobact
xylosoxidan
gramposit
bacteria
found
patient
aureu
two
betahemolyt
streptococci
group
f
streptococcu
pneumonia
among
aureu
isol
nine
methicillin
resist
wherea
gramneg
isol
resist
ceftriaxon
repres
antibiot
typic
prescrib
pneumonia
patient
without
risk
factor
antibiot
resist
mean
durat
occurr
nvhap
hospit
day
ae
characterist
case
patient
control
subject
list
tabl
patient
nvhap
like
higher
baselin
comorbid
admiss
base
charlson
comorbid
index
chronic
obstruct
pulmonari
diseas
patient
outcom
shown
tabl
patient
nvhap
statist
like
die
hospit
stay
compar
patient
without
nvhap
vs
p
similarli
patient
nvhap
like
requir
transfer
icu
vs
p
mechan
ventil
vs
p
longer
hospit
length
stay
median
vs
day
p
thirtyday
hospit
readmiss
rate
similar
two
studi
group
adjust
odd
ratio
condit
logist
regress
variabl
evalu
associ
hospit
mortal
present
tabl
nvhap
adjust
ci
along
mechan
ventil
increas
charlson
comorbid
score
associ
greater
risk
hospit
mortal
hosmerlemeshow
test
suggest
model
fit
data
p
mortal
greater
patient
nvhap
stratifi
charlson
comorbid
index
fig
studi
found
occurr
nvhap
associ
advers
outcom
includ
greater
risk
hospit
mortal
hospit
resourc
use
also
found
greater
patient
nvhap
develop
evidenc
greater
icu
admiss
need
mechan
ventil
longer
length
stay
thirtyday
hospit
readmiss
found
differ
patient
without
nvhap
also
found
viral
caus
nvhap
common
account
case
casecontrol
studi
identifi
strong
associ
hospit
mortal
nvhap
recent
routin
applic
commerci
avail
viral
multiplex
test
crotti
despit
lower
proport
identifi
pathogen
patient
nvhap
compar
vap
type
microbiolog
isol
clinic
outcom
similar
regardless
whether
pneumonia
acquir
without
mechan
ventil
find
would
suggest
patientspecif
find
sever
ill
immun
function
may
import
factor
predispos
nosocomi
pneumonia
previou
intub
moreov
type
patient
receiv
similar
empir
antibiot
treatment
benefit
prevent
measur
preferenti
direct
intub
individu
hospitalbas
qualityimprov
initi
primarili
focus
prevent
occurr
vap
nvhap
howev
difficult
demonstr
attribut
mortal
vap
overal
sever
ill
risk
ventil
patient
popul
may
account
inabl
major
vap
prevent
studi
demonstr
reduct
mortal
data
suggest
nvhap
associ
signific
morbid
mortal
excess
prevent
nvhap
could
potenti
improv
patient
outcom
emerg
mdr
pathogen
caus
hap
also
result
greater
administr
inappropri
initi
antimicrobi
therapi
associ
excess
patient
mortal
mdr
infect
nvhap
increasingli
common
mani
part
world
result
delay
administr
appropri
antibiot
therapi
moreov
attribut
mortal
hap
may
greater
associ
vap
lower
sever
ill
exist
baselin
patient
hap
compar
vap
sever
limit
studi
recogn
first
retrospect
design
allow
determin
caus
mortal
furthermor
possibl
identifi
case
nvhap
given
use
respiratori
cultur
result
intern
classif
diseas
ninth
revis
code
screen
studi
entri
purpos
done
obtain
patient
cohort
treat
physician
high
enough
suspicion
pneumonia
obtain
microbiolog
cultur
second
data
deriv
singl
center
necessarili
limit
generaliz
find
result
may
reflect
one
might
see
institut
exampl
barnesjewish
hospit
region
referr
pattern
includ
commun
hospit
region
longterm
acut
care
hospit
nurs
home
chronic
wound
dialysi
infus
clinic
patient
transfer
set
like
infect
potenti
antibioticresist
bacteria
may
explain
rel
high
rate
infect
potenti
antibioticresist
gramneg
bacteria
aureu
third
given
sampl
size
may
lack
power
identifi
import
confound
could
affect
mortal
end
point
fourth
use
protocol
obtain
specif
type
cultur
sampl
patient
rather
defer
evalu
treat
physician
may
contribut
sampl
error
identifi
case
nvhap
fifth
limit
number
match
variabl
maxim
number
patient
nvhap
studi
analysi
may
contribut
unidentifi
differ
case
control
popul
sever
ill
admiss
diagnos
may
contribut
outcom
differ
observ
final
exclud
possibl
bacteri
coinfect
present
among
patient
viral
caus
nvhap
antibiot
administr
may
limit
abil
convent
cultur
method
identifi
antibioticsuscept
bacteria
set
summari
data
suggest
occurr
nvhap
associ
advers
patient
outcom
caus
bacteri
viral
pathogen
intervent
studi
aim
prevent
nvhap
requir
determin
whether
consequ
nvhap
avoid
patient
outcom
improv
